IRON
NASDAQ
US
Disc Medicine, Inc. - Common Stock
$65,18
▲ +$0,40
(+0,62%)
Vol. 570K
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$3.0B
ROE
-31,6%
D/E
5,05
Beta
0,88
52W
$31–$100
Consenso Wall Street
19 analisti · Apr 20267
Acquisto forte
11
Compra
1
Mantieni
0
Vendi
0
Vendita forte
94,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
TVTX
Travere Therapeutics Inc
$3.4B
ORKA
Oruka Therapeutics Inc
$1.5B
VCYT
Veracyte Inc
P/E 110,3
$3.3B
BEAM
Beam Therapeutics Inc
$2.8B
KOD
Kodiak Sciences Inc
$1.7B
IMNM
Immunome Inc
$2.4B
SRPT
Sarepta Therapeutics Inc
$2.3B
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
GRAL
Grail Inc
$3.3B
RLAY
Relay Therapeutics Inc
$1.5B
Utili
Tasso di battuta: 50,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-1,78 | $-1,64 | +$0,14 |
| Set 2025 | $-1,49 | $-1,77 | $-0,28 |
| Giu 2025 | $-1,18 | $-1,58 | $-0,40 |
| Mar 2025 | $-1,16 | $-1,02 | +$0,14 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — | — |
| Utile netto | — | -$29.5M | -$34.1M | -$55.2M | -$62.3M | -$60.5M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -26.6% | -26.6% | -26.6% | -26.6% | -31.6% | -31.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 4.68 | 4.68 | 4.68 | 4.68 | 5.05 | 5.05 |
| Current Ratio | 32.11 | 32.11 | 32.11 | 32.11 | 23.45 | 23.45 |
Rapporti chiave
ROA (TTM)
-29,0%
P/B
4,2
EPS (TTM)
$-5,35
CF/Share
$-3,60
52W High
$99,50
52W Low
$30,82
$30,82
Intervallo 52 settimane
$99,50
Salute finanziaria
Flusso di cassa libero
-$43.3M
Debito netto
-$60.1M
Liquidità
$91.1M
Debito totale
$31.0M
Aggiornato al Dic 31, 2025
Як IRON виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка IRON vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
4,3
▲
73%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість IRON vs аналоги Biotechnology
ROE
-31,6%
▲
53%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
—
▼
0%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-29,0%
▲
38%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя IRON vs аналоги Biotechnology
D/E ratio
5,1
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
23,5
▲
428%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
0,9
▼
10%
sotto
peer
(1,0)
vs Peer
vs Settore
Meno volatile
Радар фундаменталів IRON
IRON
Mediana peer
Industria
IRON прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
IRON vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
SAVAGE WILLIAM JACOB
Officer · Mar 02
7378 shs
FRANCHI JEAN M
Chief Financial Officer · Feb 25
353 shs
FRANCHI JEAN M
Chief Financial Officer · Feb 18
11156 shs
QUISEL JOHN D
Chief Executive Officer · Feb 17
13264 shs
STEPHENSON PAMELA
Officer · Feb 17
5531 shs
YU JONATHAN YEN-WEN
Chief Operating Officer · Feb 17
3231 shs
SAVAGE WILLIAM JACOB
Officer · Feb 17
3256 shs
KHARA RAHUL
Officer · Feb 17
2853 shs
QUISEL JOHN D
Chief Executive Officer · Feb 10
55200 shs
FRANCHI JEAN M
Chief Financial Officer · Feb 10
19000 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 34,5%FMR, LLC
14,28%
$329.6M
Blackrock Inc.
5,96%
$137.6M
RA Capital Management, L.P.
5,18%
$119.5M
Vanguard Group Inc
4,63%
$106.9M
Price (T.Rowe) Associates I…
4,45%
$102.7M
Aggiornato al Dic 31, 2025